|
FIGHT-302: Phase III study of first-line (1L) pemigatinib (PEM) versus gemcitabine (GEM) plus cisplatin (CIS) for cholangiocarcinoma (CCA) with FGFR2 fusions or rearrangements. |
|
|
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Abbvie; Amgen; Amgen; Amgen; Amgen; Amgen (Inst); Amgen (Inst); AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Immuneering; Immuneering; Immuneering; Immuneering; Imugene; Imugene; Imugene; Imugene; Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Lilly; Lilly; Lilly; Lilly; Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); NCCN; NCCN; NCCN; NCCN; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Regeneron; Regeneron; Regeneron; Regeneron; Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Sirtex Medical; Sirtex Medical; Sirtex Medical; Sirtex Medical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical |
Research Funding - NCCN; NCCN; NCCN; NCCN; NCI; NCI; NCI; NCI; Oncolytics; Oncolytics; Oncolytics; Oncolytics |
Other Relationship - ARMO BioSciences; ARMO BioSciences; ARMO BioSciences; ARMO BioSciences; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Exelixis; Exelixis; Exelixis; Exelixis; Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Polaris; Polaris; Polaris; Polaris; Sillajen; Sillajen; Sillajen; Sillajen |
|
|
Honoraria - Ipsen; Ipsen; Ipsen; Ipsen |
Consulting or Advisory Role - Agios; Agios; Agios; Agios; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Debiopharm Group; Debiopharm Group; Debiopharm Group; Debiopharm Group; Delcath Systems; Delcath Systems; Delcath Systems; Delcath Systems; Genoscience Pharma; Genoscience Pharma; Genoscience Pharma; Genoscience Pharma; Incyte; Incyte; Incyte; Incyte; Ipsen; Ipsen; Ipsen; Ipsen; Keocyt; Keocyt; Keocyt; Keocyt; Merck; Merck; Merck; Merck; Mundipharma; Mundipharma; Mundipharma; Mundipharma; Novartis; Novartis; Novartis; Novartis; Nucana; Nucana; Nucana; Nucana; PCI Biotech; PCI Biotech; PCI Biotech; PCI Biotech; Pfizer; Pfizer; Pfizer; Pfizer; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Pieris Pharmaceuticals; QED Therapeutics; QED Therapeutics; QED Therapeutics; QED Therapeutics; SERVIER; SERVIER; SERVIER; SERVIER; Wren Laboratories; Wren Laboratories; Wren Laboratories; Wren Laboratories |
Speakers' Bureau - Imaging Equipment Limited; Imaging Equipment Limited; Imaging Equipment Limited; Imaging Equipment Limited; Ipsen; Ipsen; Ipsen; Ipsen; Novartis; Novartis; Novartis; Novartis; Nucana; Nucana; Nucana; Nucana |
Research Funding - Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst) |
Travel, Accommodations, Expenses - Celgene; Celgene; Celgene; Celgene; Nucana; Nucana; Nucana; Nucana; Pfizer; Pfizer; Pfizer; Pfizer |
|
|
Consulting or Advisory Role - Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; Halozyme; Halozyme; Halozyme; Halozyme; Lilly; Lilly; Lilly; Lilly; Merck KGaA; Merck KGaA; Merck KGaA; Merck KGaA; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Novartis; Novartis; Novartis; Novartis; Roche; Roche; Roche; Roche; SERVIER; SERVIER; SERVIER; SERVIER |
Research Funding - amgen (Inst); amgen (Inst); amgen (Inst); amgen (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); SERVIER (Inst); SERVIER (Inst); SERVIER (Inst); SERVIER (Inst) |
|
|
Honoraria - Abbvie; Abbvie; Abbvie; Abbvie; Amgen; Amgen; Amgen; Amgen; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Eisai; Eisai; Eisai; Eisai; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Ipsen; Ipsen; Ipsen; Ipsen; Lilly; Lilly; Lilly; Lilly; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi |
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; ArQule; ArQule; ArQule; ArQule; Baxter; Baxter; Baxter; Baxter; Bayer; Bayer; Bayer; Bayer; Celgene; Celgene; Celgene; Celgene; Eisai; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis; Exelixis; Hengrui Therapeutics; Hengrui Therapeutics; Hengrui Therapeutics; Hengrui Therapeutics; Incyte; Incyte; Incyte; Incyte; Ipsen; Ipsen; Ipsen; Ipsen; Italfarmaco; Italfarmaco; Italfarmaco; Italfarmaco; Lilly; Lilly; Lilly; Lilly; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi; Sirtex Medical; Sirtex Medical; Sirtex Medical; Sirtex Medical |
Travel, Accommodations, Expenses - ArQule; ArQule; ArQule; ArQule; Ipsen; Ipsen; Ipsen; Ipsen |
|
|
Honoraria - Abbvie; Abbvie; Abbvie; Abbvie; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; EA Pharma; EA Pharma; EA Pharma; EA Pharma; Eisai; Eisai; Eisai; Eisai; Fujifilm; Fujifilm; Fujifilm; Fujifilm; J-Pharma; J-Pharma; J-Pharma; J-Pharma; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Lilly Japan; Lilly Japan; Lilly Japan; Lilly Japan; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Mochida Pharmaceutical Co. Ltd.; Mochida Pharmaceutical Co. Ltd.; Mochida Pharmaceutical Co. Ltd.; Mochida Pharmaceutical Co. Ltd.; MSD; MSD; MSD; MSD; Nihon Servier; Nihon Servier; Nihon Servier; Nihon Servier; Nippon Kayaku; Nippon Kayaku; Nippon Kayaku; Nippon Kayaku; Novartis; Novartis; Novartis; Novartis; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Pfizer; Pfizer; Pfizer; Pfizer; Sanofi; Sanofi; Sanofi; Sanofi; Sawai Pharmaceutical Co; Sawai Pharmaceutical Co; Sawai Pharmaceutical Co; Sawai Pharmaceutical Co; Shionogi; Shionogi; Shionogi; Shionogi; Shire; Shire; Shire; Shire; Sumitomo Dainippon; Sumitomo Dainippon; Sumitomo Dainippon; Sumitomo Dainippon; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda; Teijin Pharma; Teijin Pharma; Teijin Pharma; Teijin Pharma; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha |
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Eisai; Eisai; Eisai; Eisai; Fujifilm; Fujifilm; Fujifilm; Fujifilm; J-Pharma; J-Pharma; J-Pharma; J-Pharma; Lilly Japan; Lilly Japan; Lilly Japan; Lilly Japan; MSD; MSD; MSD; MSD; Novartis; Novartis; Novartis; Novartis; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Otsuka; Otsuka; Otsuka; Otsuka; Shire; Shire; Shire; Shire; Sumitomo Dainippon; Sumitomo Dainippon; Sumitomo Dainippon; Sumitomo Dainippon; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takara Bio; Takara Bio; Takara Bio; Takara Bio; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha |
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); J-Pharma (Inst); J-Pharma (Inst); J-Pharma (Inst); J-Pharma (Inst); Kyowa Hakko Kirin (Inst); Kyowa Hakko Kirin (Inst); Kyowa Hakko Kirin (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Lilly Japan (Inst); Lilly Japan (Inst); Lilly Japan (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); NanoCarrier (Inst); NanoCarrier (Inst); NanoCarrier (Inst); NanoCarrier (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Sumitomo Dainippon (Inst); Sumitomo Dainippon (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Yakult Honsha (Inst); Yakult Honsha (Inst); Yakult Honsha (Inst); Yakult Honsha (Inst) |
|
|
Honoraria - Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha |
Consulting or Advisory Role - Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Otsuka; Otsuka; Otsuka; Otsuka; Shire; Shire; Shire; Shire; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical |
Speakers' Bureau - Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Otsuka; Otsuka; Otsuka; Otsuka; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha |
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Baxalta/Shire (Inst); Baxalta/Shire (Inst); Baxalta/Shire (Inst); Baxalta/Shire (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Merck Serono; Merck Serono; Merck Serono; Merck Serono; SERVIER; SERVIER; SERVIER; SERVIER |
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Basilea; Basilea; Basilea; Basilea; Bayer; Bayer; Bayer; Bayer; Incyte; Incyte; Incyte; Incyte; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Roche; Roche; Roche; Roche; SERVIER; SERVIER; SERVIER; SERVIER |
Speakers' Bureau - Amgen; Amgen; Amgen; Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene |
Research Funding - Amgen; Amgen; Amgen; Amgen |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb/Medarex; Bristol-Myers Squibb/Medarex; Bristol-Myers Squibb/Medarex; Bristol-Myers Squibb/Medarex; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; SERVIER; SERVIER; SERVIER; SERVIER |
|
|
Honoraria - Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; Celgene; Celgene; Celgene; Celgene; ERYTECH Pharma; ERYTECH Pharma; ERYTECH Pharma; ERYTECH Pharma; Merck KGaA; Merck KGaA; Merck KGaA; Merck KGaA; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Servier; Servier; Servier; Servier; Shire; Shire; Shire; Shire; Sirtex Medical; Sirtex Medical; Sirtex Medical; Sirtex Medical |
Consulting or Advisory Role - ERYTECH Pharma; ERYTECH Pharma; ERYTECH Pharma; ERYTECH Pharma; Incyte; Incyte; Incyte; Incyte; Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre; Roche Pharma AG; Roche Pharma AG; Roche Pharma AG; Roche Pharma AG; Shire; Shire; Shire; Shire; Sirtex medical; Sirtex medical; Sirtex medical; Sirtex medical |
Speakers' Bureau - Celgene; Celgene; Celgene; Celgene; Merck KGaA; Merck KGaA; Merck KGaA; Merck KGaA; SERVIER; SERVIER; SERVIER; SERVIER; Sirtex Medical; Sirtex Medical; Sirtex Medical; Sirtex Medical |
Research Funding - Merck KGaA (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Sirtex Medical (Inst); Sirtex Medical (Inst); Sirtex Medical (Inst); Sirtex Medical (Inst) |
|
|
Stock and Other Ownership Interests - AVEO; AVEO; AVEO; AVEO; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline |
Consulting or Advisory Role - Agios (Inst); Agios (Inst); Agios (Inst); Agios (Inst); ArQule (Inst); ArQule (Inst); ArQule (Inst); ArQule (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Fujifilm (Inst); Fujifilm (Inst); Fujifilm (Inst); Fujifilm (Inst); G1 Therapeutics; G1 Therapeutics; G1 Therapeutics; G1 Therapeutics; Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Inspyr Therapeutics; Inspyr Therapeutics; Inspyr Therapeutics; Inspyr Therapeutics; Insys Therapeutics (Inst); Insys Therapeutics (Inst); Insys Therapeutics (Inst); Insys Therapeutics (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pieris Pharmaceuticals (Inst); Pieris Pharmaceuticals (Inst); Pieris Pharmaceuticals (Inst); Pieris Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); TD2; TD2; TD2; TD2 |
Research Funding - Agios (Inst); Agios (Inst); Agios (Inst); Agios (Inst); ARIAD (Inst); ARIAD (Inst); ARIAD (Inst); ARIAD (Inst); BiolineRx (Inst); BiolineRx (Inst); BiolineRx (Inst); BiolineRx (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Dicerna (Inst); Dicerna (Inst); Dicerna (Inst); Dicerna (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); ImClone Systems (Inst); ImClone Systems (Inst); ImClone Systems (Inst); ImClone Systems (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Isis Pharmaceuticals (Inst); Isis Pharmaceuticals (Inst); Isis Pharmaceuticals (Inst); Isis Pharmaceuticals (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); miRNA Therapeutics (Inst); miRNA Therapeutics (Inst); miRNA Therapeutics (Inst); miRNA Therapeutics (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Senhwa Biosciences (Inst); Senhwa Biosciences (Inst); Senhwa Biosciences (Inst); Senhwa Biosciences (Inst); Sillajen (Inst); Sillajen (Inst); Sillajen (Inst); Sillajen (Inst); Sun Biopharma (Inst); Sun Biopharma (Inst); Sun Biopharma (Inst); Sun Biopharma (Inst); Sun Biopharma (Inst); Sun Biopharma (Inst); Sun Biopharma (Inst); Sun Biopharma (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Threshold Pharmaceuticals (Inst); Threshold Pharmaceuticals (Inst); Threshold Pharmaceuticals (Inst); Threshold Pharmaceuticals (Inst); Toray Industries (Inst); Toray Industries (Inst); Toray Industries (Inst); Toray Industries (Inst) |
Travel, Accommodations, Expenses - ArQule; ArQule; ArQule; ArQule; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Celgene; Celgene; Celgene; Celgene |
|
|
No Relationships to Disclose |
|
|
Employment - Incyte; Incyte; Incyte; Incyte |
Stock and Other Ownership Interests - Incyte; Incyte; Incyte; Incyte |
|
|
Employment - Incyte; Incyte; Incyte; Incyte |
Stock and Other Ownership Interests - Incyte; Incyte; Incyte; Incyte |
|
|
Employment - Incyte; Incyte; Incyte; Incyte |
Stock and Other Ownership Interests - Incyte; Incyte; Incyte; Incyte |
|
|
Employment - Halozyme; Halozyme; Halozyme; Halozyme |
Stock and Other Ownership Interests - Halozyme; Halozyme; Halozyme; Halozyme |
Patents, Royalties, Other Intellectual Property - Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof: Sep.30, 2014 (Inst); Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof: Sep.30, 2014 (Inst); Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof: Sep.30, 2014 (Inst); Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof: Sep.30, 2014 (Inst) |
|
|
Honoraria - Amgen; Amgen; Amgen; Amgen; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Delcath Systems; Delcath Systems; Delcath Systems; Delcath Systems; Lilly; Lilly; Lilly; Lilly; MSD; MSD; MSD; MSD; Novartis; Novartis; Novartis; Novartis; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi |
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Baxalta; Baxalta; Baxalta; Baxalta; Bayer; Bayer; Bayer; Bayer; Delcath Systems; Delcath Systems; Delcath Systems; Delcath Systems; Lilly; Lilly; Lilly; Lilly; Novartis; Novartis; Novartis; Novartis; Roche; Roche; Roche; Roche |
Research Funding - Novartis; Novartis; Novartis; Novartis |
Travel, Accommodations, Expenses - Bayer; Bayer; Bayer; Bayer; Ipsen; Ipsen; Ipsen; Ipsen; Roche; Roche; Roche; Roche |